Roche and Eli Lilly Obtain FDA Authorization for Alzheimer’s Blood Test

**The FDA has authorized Elecsys pTau217, a blood test developed by Roche in collaboration with Eli Lilly to help assess indications of Alzheimer’s disease in individuals aged 55 and older who show signs, symptoms, or complaints of cognitive decline. The test can be used on analyzers installed in the United States, although its results must be interpreted alongside other clinical data and will not function as an independent diagnosis.

• The FDA authorized Elecsys pTau217 to help assess indications of Alzheimer’s disease in individuals aged 55 and older with signs, symptoms, or complaints of cognitive decline.
• Roche indicated that the analysis can be performed on more than 4,500 analyzers installed in the United States.
• There is no confirmation in the available evidence that Labcorp and Quest Diagnostics will offer Elecsys pTau217; the price of the test has not been disclosed.

The U.S. Food and Drug Administration (FDA) has authorized a blood test developed by Roche in collaboration with Eli Lilly to help assess indications of Alzheimer’s disease in individuals aged 55 and older who present signs, symptoms, or complaints of cognitive decline. The analysis, named Elecsys pTau217, aims to provide physicians with information about the likelihood that a patient has brain changes associated with the disease, although its results do not replace a comprehensive clinical evaluation.

Roche described the test as a biomarker-based tool that can help identify both patients with probable alterations associated with Alzheimer’s and those who likely do not have them. The U.S. authorization comes after the FDA approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test from Fujirebio in May 2025, which was the first blood test of its kind authorized by the agency.

An Alternative to More Complex Tests

The search for blood biomarkers responds, in part, to the practical difficulties of traditional methods for detecting amyloid protein, a substance linked to Alzheimer’s disease. These procedures often require positron emission tomography scans, known as PET, or analysis of cerebrospinal fluid, techniques that can be costly, invasive, and less accessible for some patients.

Elecsys pTau217 analyzes a biological signal associated with the brain changes that physicians study in the context of Alzheimer’s. The test is not intended to replace medical imaging, clinical history, or specialist assessment, but to provide additional data that helps decide which patients may need confirmatory studies.

Roche emphasized that the test is not designed to serve as an independent diagnosis, so its results must be analyzed alongside other clinical information. This limitation is relevant because a blood marker can guide an evaluation, but does not solely determine the cause of cognitive decline or confirm the disease in isolation.

The FDA authorization also reflects the growing interest in detecting Alzheimer’s-related changes earlier. A more timely diagnosis can help physicians and families organize care, although the concrete value of each result will depend on the clinical context and additional tests that may be indicated.

Availability in the Laboratory Network

According to Roche, Elecsys pTau217 can be performed on more than 4,500 laboratory analyzers from the company that are already installed in the United States. The existing infrastructure could facilitate broader adoption, as centers would not necessarily have to incorporate entirely new equipment to begin processing the test.

The available evidence does not confirm that Labcorp and Quest Diagnostics have announced plans to specifically offer Elecsys pTau217 through their networks. Quest has communicated the availability of p-tau biomarker services, and Labcorp announced plans to offer another Roche test, Elecsys pTau181, but these precedents do not allow us to assert that both companies will commercialize this pTau217 test.

Roche did not disclose the price of Elecsys pTau217. The final cost for users could become a decisive factor in determining whether the test fulfills its promise to expand access, especially when traditional methods already face economic and logistical barriers.

The availability of equipment and laboratory networks does not guarantee that all patients can undergo the analysis. Medical prescription, insurance coverage, the ability of professionals to interpret the biomarker, and the availability of complementary studies when results are ambiguous will also be important.

An Expanding Diagnostic Market

The FDA's decision comes as pharmaceutical companies and diagnostic developers seek to respond to the demand for less complex tools to assess cognitive decline. The expectation of earlier treatments has heightened interest in identifying biological signals before symptoms progress, making blood tests a competitive area both commercially and scientifically.

Elecsys pTau217 is not the first blood test authorized by the FDA aimed at facilitating Alzheimer's assessment. Lumipulse, manufactured by Fujirebio, became the first blood test authorized by the U.S. agency in 2025 to support this process.

The arrival of new tests may expand options for doctors, but it also requires clear communication about what each result means. A result suggesting changes related to Alzheimer’s does not necessarily equate to a definitive confirmation, just as a result that does not suggest such changes must be interpreted within each person's medical history.

The competition among Roche, Eli Lilly, Fujirebio, and laboratory networks occurs in a field where accuracy and clinical utility are as important as ease of access. The expansion of these tools will depend on how they are integrated into consultations, the evidence supporting their use, and the healthcare system's ability to support patients after the analysis.

What the Authorization Implies

The FDA authorization allows Elecsys pTau217 to be used as support for identifying signs of Alzheimer’s in the patient group covered by the authorization. It does not mean that the test can be used without medical supervision or that it automatically turns a blood test into a definitive diagnosis of the disease.

For individuals with cognitive decline, the examination could represent a less invasive alternative to a cerebrospinal fluid extraction and potentially more accessible than a PET scan. However, the decision to request it and the interpretation of its results will continue to depend on medical evaluation and available clinical information.

For Roche, the ability to use thousands of already installed analyzers offers an operational advantage over solutions that require specialized infrastructure. For Eli Lilly, its involvement links the diagnostic tool with the broader effort to identify patients at stages where early assessment and treatment may be more relevant.

The next challenge will be to demonstrate that expanded access translates into timely assessments and better-informed clinical decisions. While the price of the test remains undisclosed and a specific offer of Elecsys pTau217 by Labcorp and Quest Diagnostics has not been confirmed, the market will continue to watch whether blood tests can become a practical and responsible avenue to support Alzheimer's detection.